4-(Diethylamino)But-2-Ynyl Acetate Bulk Price Global Manufacturer Analysis
- High Purity Standards: Consistent availability of CAS 22396-77-6 with ≥98% industrial purity for reliable organic synthesis.
- Supply Chain Stability: Direct sourcing from established facilities ensures reduced lead times and secure logistics.
- Commercial Flexibility: Volume-based pricing tiers and custom quotations available for large-scale pharmaceutical procurement.
4-(Diethylamino)but-2-ynyl acetate, commonly identified by CAS 22396-77-6, serves as a critical chemical building block in the pharmaceutical industry. Primarily utilized as an Oxybutynin intermediate, this compound requires stringent quality control to ensure the efficacy and safety of the final active pharmaceutical ingredient (API). Procurement professionals prioritize suppliers who can demonstrate robust manufacturing processes and consistent batch-to-batch reproducibility. Understanding the technical specifications and commercial dynamics of this high purity liquid is essential for maintaining uninterrupted production schedules.
The synthesis route for this acetate derivative typically involves the acetylation of the corresponding amino-alcohol precursor. Maintaining industrial purity during this transformation is vital, as impurities can propagate through downstream reactions, complicating purification steps in the final API manufacture. Leading facilities adhere to Good Manufacturing Practices (GMP) to mitigate risks associated with contamination. When evaluating suppliers for 4-(Diethylamino)but-2-ynyl Acetate, buyers should verify the availability of comprehensive Certificates of Analysis (COA) that detail impurity profiles and physical constants.
Technical Specifications and Physical Properties
For process chemists and procurement managers, accurate physical data is necessary for handling, storage, and reactor design. The compound is characterized by specific boiling points and density values that influence distillation and separation processes. Below is a summary of the key physical and chemical properties derived from standard safety data sheets and technical documentation.
| Property | Value / Description |
|---|---|
| CAS Number | 22396-77-6 |
| Synonyms | 1-Acetoxy-4-diethylamino-2-butyne, 4-diethylamino-2-butynyl acetate |
| Boiling Point | 217-218ºC |
| Flash Point | 103ºC |
| Density | 0.961 g/cm³ |
| Vapor Pressure | 0.0242 mmHg at 25°C |
| Appearance | High purity liquid |
Safety protocols dictate that this substance be handled with care due to its classification under GHS standards. It is categorized as causing skin irritation (Category 2) and serious eye irritation (Category 2). Furthermore, it may cause respiratory irritation upon single exposure. Proper personal protective equipment (PPE), including safety glasses with side-shields and impervious gloves, is mandatory during handling. Storage conditions require a cool, well-ventilated place with containers kept tightly closed to prevent degradation and minimize exposure risks.
Volume-Based Pricing Tiers for Bulk Orders
The bulk price for 4-(Diethylamino)but-2-ynyl acetate fluctuates based on order volume, raw material costs, and purification requirements. Market analysis indicates that purity levels between 98% and 99% command different price points, with pharma grade specifications often incurring a premium due to additional testing and documentation. Larger volume commitments typically unlock significant cost reductions, making long-term supply agreements advantageous for high-volume API manufacturers.
Pricing structures are generally segmented into kilogram, multi-kilogram, and metric ton scales. Smaller quantities often face higher unit costs due to fixed packaging and quality control overheads. Conversely, metric ton procurement allows for optimized production runs and logistics consolidation. A reliable global manufacturer will provide transparent pricing tiers that reflect these economies of scale without compromising on the industrial purity required for sensitive organic synthesis applications.
Direct Sourcing from Global Manufacturer Facilities
Securing a stable supply chain involves partnering with entities that control the production process from start to finish. NINGBO INNO PHARMCHEM CO.,LTD. operates as a premier global manufacturer offering these technical advantages and bulk supply capabilities. Direct sourcing eliminates intermediaries, reducing the risk of counterfeit materials and ensuring that the synthesis route aligns with regulatory expectations. This direct relationship facilitates better communication regarding technical queries, custom packaging, and shipment scheduling.
Lead times vary across the industry, typically ranging from a few days to several weeks depending on inventory levels and production scheduling. Facilities with robust inventory management can offer shorter lead times, such as 3 to 7 days for standard orders, while custom batches may require up to 30 days. Procurement strategies should account for these variables to prevent production bottlenecks. Establishing a partnership with a facility that maintains consistent stock levels of this key intermediate is crucial for just-in-time manufacturing environments.
Requesting Custom Quotations for Large Scale Procurement
For large-scale procurement, standard catalog pricing is often insufficient. Buyers should request custom quotations that account for specific delivery terms, packaging requirements, and regulatory documentation needs. A comprehensive quotation should include details on the COA, stability data, and any available regulatory support files. Engaging with a supplier who understands the nuances of pharmaceutical intermediates ensures that all compliance requirements are met efficiently.
When initiating negotiations, clearly define the required purity specifications and acceptable impurity limits. Suppliers capable of meeting tight specifications often provide additional value through technical support and process optimization advice. By leveraging the expertise of a dedicated global manufacturer, companies can secure a competitive edge in the production of downstream therapeutics. Ultimately, the goal is to establish a reliable, cost-effective supply chain that supports the continuous manufacture of essential medications without compromise on quality or safety.